Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
- Authors
- Cho, Raymond Y; Ford, Judith M; Krystal, John H; Laruelle, Marc; Cuthbert, Bruce; Carter, Cameron S
- Year
- 2005
- Journal
- Schizophrenia bulletin
- PMID
- 16166611
- DOI
- 10.1093/schbul/sbi050
"Measurement and Treatment Research to Improve Cognition in Schizophrenia" or MATRICS is a National Institute of Mental Health (NIMH)--sponsored research effort to drive novel drug development for the treatment of cognitive impairments in schizophrenia. On September 9-10, 2004, MATRICS convened representatives from NIMH, academia, and industry for the final of a series of consensus-oriented conferences, with this meeting entitled "New Approaches to Assessing and Improving Cognition in Schizophrenia." In this article, we present a summary of the discussions that focused on functional neuroimaging and electrophysiology biomarkers, outlining the research priorities, which included developing further consensus regarding the cognitive processes that are critical to examine in schizophrenia and the paradigms to examine them, resolving issues of test-retest reliability and discrepant findings in the literature, and additional basic research regarding the methods before fully implementing these paradigms in drug trials. Also summarized are the relative advantages and disadvantages of the different approaches and varying perspectives among the participants regarding these tools. Our hope is that this report will help guide and further stimulate coordinated efforts among researchers, industry, and funding agencies in meeting the urgent need for novel pharmacotherapeutics for cognitive impairments in schizophrenia and useful neurobiological indexes for tracking the resulting improvements in cognitive function.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Advances in Electrophysiological Research. | 2015 | 26259089 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Advances in neurochemical measurements: A review of biomarkers and devices for the development of closed-loop deep brain stimulation systems. | Rojas Cabrera JM et al. | — | 2020 | → |
| Advances in Electrophysiological Research. | Kamarajan C et al. | — | 2015 | → |
| Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. | Knott V et al. | — | 2015 | → |
| CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. | Knott V et al. | — | 2014 | → |
| Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study. | Knott V et al. | — | 2014 | → |
| Test-retest reliability of N400 event-related brain potential measures in a word-pair semantic priming paradigm in patients with schizophrenia. | Boyd JE et al. | — | 2014 | → |
| A review of recent literature employing electroencephalographic techniques to study the pathophysiology, phenomenology, and treatment response of schizophrenia. | Hasey GM et al. | — | 2013 | → |
| Test-retest reliability and stability of N400 effects in a word-pair semantic priming paradigm. | Kiang M et al. | — | 2013 | → |
| Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. | Light GA et al. | — | 2012 | → |
| Core dysfunction in schizophrenia: electrophysiology trait biomarkers. | Koychev I et al. | — | 2012 | → |
| Striatal function in relation to negative symptoms in schizophrenia. | Ehrlich S et al. | — | 2012 | → |
| Cognitive control deficits in schizophrenia: mechanisms and meaning. | Lesh TA et al. | — | 2011 | → |
| Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. | Romón T et al. | — | 2011 | → |
| Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task. | Musso F et al. | — | 2011 | → |
| Reproducibility of fMRI activations during a story listening task in patients with schizophrenia. | Maïza O et al. | — | 2011 | → |
| Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. | Barch DM et al. | — | 2011 | → |
| Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia. | Shrivastava AK et al. | — | 2010 | → |
| Impact of cognitive performance on the reproducibility of fMRI activation in schizophrenia. | Maïza O et al. | — | 2010 | → |
| The relationship between preattentive sensory processing deficits and age in schizophrenia patients. | Kiang M et al. | — | 2009 | → |
| Endophenotypes in psychiatric genetics. | Walters JT et al. | — | 2007 | → |
| Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD). | Stover E et al. | — | 2007 | → |
| The quest for developing new treatments from imaging techniques: promises, problems and future potential. | Minzenberg MJ et al. | — | 2007 | → |
| Neuroimaging in late-life depression. | Vaishnavi S et al. | — | 2006 | → |
| Pathophysiologically based treatment interventions in schizophrenia. | Lewis DA et al. | — | 2006 | → |